Physician profile
Deke Steven Eberhard
NPI 1982135299
$1,607.06
in general payments reported to CMS, 2019-2025
18 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2021: $283 · 2022: $175 · 2023: $322 · 2024: $275 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $344.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $256.70 | 2021-2025 | |
| Lilly USA, LLC | $220.61 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $206.29 | 2020-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $115.85 | 2021-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $111.85 | 2021-2022 | |
| Amgen INC. | $67.06 | 2021-2025 | Repatha |
| Glaxosmithkline, LLC. | $41.69 | 2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $36.36 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $35.94 | 2025 | General - Vascular Intervention |
| Teva Pharmaceuticals USA, INC. | $30.46 | 2022-2023 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $30.32 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.13 | 2020-2023 | Ofev |
| Supernus Pharmaceuticals, INC. | $19.43 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $15.58 | 2025 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $15.47 | 2022 | |
| Shield Therapeutics INC | $15.37 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deke Eberhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.